Skip to content
Review Open access

Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 131 references
Medicine

TL;DR

This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer, emphasizing the transformative impact of targeted therapies and immunotherapies and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians alike.

Abstract

This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer (TNBC), emphasizing the transformative impact of targeted therapies and immunotherapies. Given TNBC’s aggressive nature and limited therapeutic options, this review provides an in-depth analysis of emerging strategies that aim to enhance patient outcomes. Within targeted therapies, we discuss molecular subtypes and evaluate the efficacy of PARP inhibitors, EGFR inhibitors, and PI3K inhibitors, integrating insights from clinical trials. The immunotherapy landscape is examined through immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, and novel vaccine-based approaches. Combination strategies are assessed, focusing on clinical efficacy, safety, and resistance mechanisms. Additionally, we highlight emerging therapeutic innovations, including bispecific antibodies, advanced drug delivery systems, and personalized medicine approaches. Beyond treatment modalities, the review addresses key challenges such as therapy resistance, biomarker-driven treatment selection, and the integration of Artificial Intelligence in TNBC management. Future directions emphasize ongoing clinical trials and evolving therapeutic paradigms aimed at improving survival and quality of life for TNBC patients. As the field progresses, a multidisciplinary approach integrating precision oncology, innovative therapeutics, and patient-centered care will be critical. In conclusion, this review encapsulates current breakthroughs and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians alike.

Read PDF

Similar papers

Review Open access Sep 2026

NEW IMMUNOTHERAPY STRATEGIES FOR MELANOMA: CHECKPOINT INHIBITORS, COMBINATION THERAPIES AND mRNA VACCINES

Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.

Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al. · 0 citations
Review

IMMUNOTHERAPY STRATEGIES FOR

This review aims to discuss current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines.

Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al. · 1 citation
Review Open access Aug 2026

Current and future therapies for triple-negative breast cancer

This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...

Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al. · 0 citations
Review Open access Sep 2026

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

This review examines the evolving landscape of ICI‐based combination therapies, including regimens that combine ICI with chemotherapy, targeted therapy, antibody–drug conjugates, antiangiogenic agents, and radiotherapy, which have expanded first‐line treatment options across multiple solid tumors and, in selected setti...

Qiong-Yue Zhang, Zhi-Lai Qin, Caijuan Guo · 0 citations
Review Sep 2026

Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.

K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.